StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$83.30−4.45 (-5.07%)

Close on Nov 13, 2026Market cap $1.23BP/E –Yield –

Inhibrx Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Inhibrx Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$123.60M. For fiscal 2025 it was -$132.54M. The highest annual figure on record is -$42.55M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.54M–
FY2024Dec 31, 2024-$329.16M–
FY2023Dec 31, 2023-$218.03M–
FY2022Dec 31, 2022-$127.89M–
FY2021Dec 31, 2021-$75.37M–
FY2020Dec 31, 2020-$66.42M–
FY2019Dec 31, 2019-$42.55M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$31.22M–
Q2 FY2026Jun 30, 2026-$31.63M–
Q1 FY2026Mar 31, 2026-$30.39M–
Q4 FY2025Dec 31, 2025-$30.36M–
Q3 FY2025Sep 30, 2025-$33.23M–
Q2 FY2025Jun 30, 2025-$26.73M–
Q1 FY2025Mar 31, 2025-$42.23M–
Q4 FY2024Dec 31, 2024-$49.24M–
Q3 FY2024Sep 30, 2024-$46.04M–
Q2 FY2024Jun 30, 2024-$160.42M–
Q1 FY2024Mar 31, 2024-$73.47M–
Q4 FY2023Dec 31, 2023-$87.99M–
Q3 FY2023Sep 30, 2023-$45.52M–
Q2 FY2023Jun 30, 2023-$41.04M–
Q1 FY2023Mar 31, 2023-$43.47M–
Q4 FY2022Dec 31, 2022-$35.20M–
Q3 FY2022Sep 30, 2022-$29.69M–
Q2 FY2022Jun 30, 2022-$34.29M–
Q1 FY2022Mar 31, 2022-$28.71M–
Q4 FY2021Dec 31, 2021-$19.10M–
Q3 FY2021Sep 30, 2021-$18.50M–
Q2 FY2021Jun 30, 2021-$19.50M–
Q1 FY2021Mar 31, 2021-$18.27M–
Q4 FY2020Dec 31, 2020-$16.84M–
Q3 FY2020Sep 30, 2020-$15.26M–
Q2 FY2020Jun 30, 2020-$16.97M–
Q1 FY2020Mar 31, 2020-$17.36M–
Q4 FY2019Dec 31, 2019-$16.22M–
Q3 FY2019Sep 30, 2019-$12.55M–

More Inhibrx Biosciences figures

See a number that looks wrong?